asenapine (Saphris)
Jump to navigation
Jump to search
Indications
Dosage
- 5-10 mg sublingual
- transdermal system FDA-approved Oct 2019
Adverse effects
- severe allergic reactions, anaphylaxis[2]
- sedation
- black box warning[3]
- increased risk of hyperglycemia
- increased risk of cerebrovascular events
- increased risk of mortality in patients with dementia
- drug adverse effects of antipsychotic agents
- drug adverse effects of atypical antipsychotic agents
- drug adverse effects of psychotropic agents
Notes
- cost: $478/month, 10 mg QD (2009)
More general terms
References
- ↑ Prescriber's Letter 16(10): 2009 Comparison of Atypical Antipsychotics Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251010&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 FDA MedWatch 09/01/11 Saphris (asenapine maleate): Drug Safety Communication: Serious Allergic Reactions http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm270600.htm
Prescriber's Letter 18(10): 2011 Saphris (Asenapine) and Serious Allergic Reactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=271008&pb=PRL (subscription needed) http://www.prescribersletter.com - ↑ 3.0 3.1 3.2 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
- ↑ U.S. FDA Approves SECUADO (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia. Business Wire. Oct 15, 2019 https://www.businesswire.com/news/home/20191015005668/en/U.S.-FDA-Approves-SECUADO%C2%AE-asenapine-Transdermal-System